BCLS Fund III Investments, LP - 31 Dec 2024 SCHEDULE 13G/A Report for Dianthus Therapeutics, Inc. Common Stock, $0.001 par value per share (DNTH)

Filing Manager
BCLS Fund III Investments, LP
Reporting Manager
BCLS Fund III Investments, LP
Security
Dianthus Therapeutics, Inc. Common Stock, $0.001 par value per share
Symbol
DNTH
Shares outstanding
30,564,852 shares
Disclosed Ownership
2,689,707 shares
Ownership
8.8%
Form type
SCHEDULE 13G/A
Filing time
14 Feb 2025, 07:54:51 UTC
Date of event
31 Dec 2024
Next filing
14 Aug 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"BCLS Fund III Investments, LP disclosed 8.8% ownership in Dianthus Therapeutics, Inc. Common Stock, $0.001 par value per share (DNTH) on 31 Dec 2024."

Quick Takeaways

  • BCLS Fund III Investments, LP filed SCHEDULE 13G/A for Dianthus Therapeutics, Inc. Common Stock, $0.001 par value per share (DNTH).
  • Disclosed ownership: 8.8%.
  • Date of event: 31 Dec 2024.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 14 Feb 2025, 07:54.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (1)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
BCLS Fund III Investments, LP 8.8% 2,689,707 0 2,689,707 /s/ Ricky Sun Ricky Sun, Partner of Bain Capital Life Sciences Investors, LLC

Sponsored